Intangible Assets (Narrative) (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Feb. 14, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Aug. 23, 2021 |
|
| Finite-Lived Intangible Assets [Line Items] | ||||||
| Impairment of intangible assets | $ 565,000 | $ 565,000 | $ 0 | |||
| Impairment of intangible assets | $ 25,000 | |||||
| Amortization of Intangible Assets | $ 49,000 | $ 123,000 | 116,000 | $ 211,000 | ||
| Patents and Licenses [Member] | ||||||
| Finite-Lived Intangible Assets [Line Items] | ||||||
| Amortization of Intangible Assets | 47,000 | |||||
| Intellectual Property [Member] | ||||||
| Finite-Lived Intangible Assets [Line Items] | ||||||
| Amortization of Intangible Assets | $ 69,000 | |||||
| RubrYc Therapeutics, Inc. [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | ||||||
| Finite-Lived Intangible Assets [Line Items] | ||||||
| Investment | $ 7,500,000 | |||||
| X | ||||||||||
- Definition The amount of investment under the stock purchase agreement. No definition available.
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|